NKG2A, a New Kid on the Immune Checkpoint Block
- 1 December 2018
- journal article
- editorial
- Published by Elsevier BV in Cell
- Vol. 175 (7), 1720-1722
- https://doi.org/10.1016/j.cell.2018.11.048
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer VaccinesCell, 2018
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosisNature Medicine, 2018
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2017
- Broadly targeted CD8 + T cell responses restricted by major histocompatibility complex EScience, 2016
- Role of non-classical MHC class I molecules in cancer immunosuppressionOncoImmunology, 2013
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- HLA-E binds to natural killer cell receptors CD94/NKG2A, B and CNature, 1998